ArticleCell reports. Medicine2025

A phase 1 trial of APG-1387, an IAP antagonist, with nab-paclitaxel and gemcitabine in patients with refractory metastatic pancreatic cancer.

Si Shi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.